180 related articles for article (PubMed ID: 35378764)
1. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
[TBL] [Abstract][Full Text] [Related]
2. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.
Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679
[TBL] [Abstract][Full Text] [Related]
3. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
[TBL] [Abstract][Full Text] [Related]
4. Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants.
Zhang L; Dutta S; Xiong S; Chan M; Chan KK; Fan TM; Bailey KL; Lindeblad M; Cooper LM; Rong L; Gugliuzza AF; Shukla D; Procko E; Rehman J; Malik AB
bioRxiv; 2021 Dec; ():. PubMed ID: 34981059
[TBL] [Abstract][Full Text] [Related]
5. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
[TBL] [Abstract][Full Text] [Related]
6. Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection.
Kim HK; Cho J; Kim E; Kim J; Yang JS; Kim KC; Lee JY; Shin Y; Palomera LF; Park J; Baek SH; Bae HG; Cho Y; Han J; Sul JH; Lee J; Park JH; Cho YW; Lee W; Jo DG
J Extracell Vesicles; 2022 Jan; 11(1):e12179. PubMed ID: 34982509
[TBL] [Abstract][Full Text] [Related]
7. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
8. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.
Chan KK; Tan TJC; Narayanan KK; Procko E
bioRxiv; 2020 Dec; ():. PubMed ID: 33398275
[TBL] [Abstract][Full Text] [Related]
9. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
[TBL] [Abstract][Full Text] [Related]
10. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
[TBL] [Abstract][Full Text] [Related]
11. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
[TBL] [Abstract][Full Text] [Related]
12. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo.
Kayabolen A; Akcan U; Özturan D; Ulbegi-Polat H; Sahin GN; Pinarbasi-Degirmenci N; Bayraktar C; Soyler G; Sarayloo E; Nurtop E; Ozer B; Guney-Esken G; Barlas T; Yildirim IS; Dogan O; Karahuseyinoglu S; Lack NA; Kaya M; Albayrak C; Can F; Solaroglu I; Bagci-Onder T
Adv Sci (Weinh); 2022 Sep; 9(27):e2201294. PubMed ID: 35896894
[TBL] [Abstract][Full Text] [Related]
13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
14. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters.
Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani H; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
bioRxiv; 2023 May; ():. PubMed ID: 37205409
[TBL] [Abstract][Full Text] [Related]
16. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
17. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
18. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Toledo EG; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RK; Rannard S; Stewart J; Owen A
bioRxiv; 2023 Mar; ():. PubMed ID: 35118468
[TBL] [Abstract][Full Text] [Related]
19. Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.
Nagata K; Utsumi D; Asaka MN; Maeda R; Shirakawa K; Kazuma Y; Nomura R; Horisawa Y; Yanagida Y; Kawai Y; Sato K; Yamaoka Y; Miyakawa K; Ryo A; Yasutomi Y; Imura A; Takaori-Kondo A
Commun Med (Lond); 2022 Nov; 2(1):152. PubMed ID: 36435945
[TBL] [Abstract][Full Text] [Related]
20. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
